Bempedoic Acid and Cardiovascular Outcomes in Statin ...
Mar 4, 2023 · The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, …
Nexletol: Uses, Dosage, Side Effects, Warnings - Drugs.com
Aug 5, 2024 · Nexletol (bempedoic acid) is an oral tablet for high cholesterol that may be used to lower the risk of heart attack and heart procedures (for example stent placement or bypass surgery), in …
Esperion settles another lawsuit to keep generic versions of ...
3 days ago · Esperion Therapeutics has filed patent infringement lawsuits against eight generic drug makers for filing U.S. Food and Drug Administration (FDA) abbreviated new drug applications …
Nexletol shows CLEAR benefit in cardiovascular outcome trial
3 days ago · New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout ...
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET ...
Mar 22, 2024 · U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, …
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET ...
ANN ARBOR, Mich., March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new …
In the cardiovascular outcomes trial [see Clinical Studies (14.1)], 16.4% of NEXLETOL-treated patients experienced clinically significant hyperuricemia reported as an adverse reaction (versus 8.2% …
Bempedoic Acid Reduces Major Adverse Cardiovascular Events ...
Tip for Patients: For patients who cannot take a statin, bempedoic acid (Nexletol) is an alternative to statin therapy for prevention of cardiovascular disease in high-risk patients without significant liver or …
NEXLIZET® & NEXLETOL® HCP Information - Official Site
The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0.5% greater than placebo …
In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)
CONCLUSION ― In one large clinical trial in statinintolerant patients who had or were at high-risk for cardiovascular disease, the oral adenosine triphosphate- citrate lyase (ACL) inhibitor bempedoic acid …